NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held in New York on May 15, which brings together institutional investors, high-net-worth individuals, corporate clients and the press with public and private company executives.
At the conference, CEO Dr Anil Diwan will share with investors the company’s progress over the last year.
The company highlighted that its lead drug asset NV-387 has successfully completed Phase 1a/1b human clinical trials in healthy subjects, with no reported adverse events, indicating excellent safety.
Additionally, NV-387 has shown strong antiviral activity against viruses from multiple families, including Coronaviruses (SARS-CoV-2, Long COVID, seasonal coronaviral infections), RSV, Influenza A, and a Smallpox/Mpox-related mouse virus in stringent, lethal viral infection animal models.
In all of these viruses, treatment with NV-387 demonstrated an improvement in survival that “substantially exceeded” or was at least comparable to already approved drugs or antiviral agents.
The company believes NV-387 could be the very first single drug that can treat all of the "tripledemic" viral infections, namely, Coronaviruses, RSV, and Influenza A.
"The ultra-broad-spectrum antiviral drug NV-387 could lead to a disruptive change in how we treat viral infections just as penicillin revolutionized how we treat bacterial infections," Dr Diwan said.
Interested parties can register for the event here.